Abstract: An assay for interferon comprises two antibodies to interferon, one labelled and at least one being a monoclonal antibody. The non-labelled antibody is suitably attached to a solid support such as polystyrene beads and the labelled antibody is suitably a radiolabelled monoclonal antibody, e.g. 125 I-NK2.
Abstract: Mixtures of monoclonal antibodies which contain effective assaying amounts of each of at least two monoclonal antibodies that bind to different antigenic sites on the antigen and are capable under appropriate conditions of binding simultaneously to an antigen are useful in enhanced sensitivity assays for the antigen. By utilizing such mixtures in diagnostic assays for important antigens such as the polypeptide human chorionic gonadotropin enhanced sensitivity can be achieved as compared with assays employing individual monoclonal antibodies.
Type:
Grant
Filed:
May 21, 1982
Date of Patent:
April 30, 1985
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Robert E. Canfield, Paul H. Ehrlich, William R. Moyle
Abstract: The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.
Type:
Grant
Filed:
January 28, 1983
Date of Patent:
April 30, 1985
Assignee:
The Government of the United States as represented by the Secretary of the Department of Health and Human Services
Inventors:
James A. Braatz, Kenneth R. McIntire, Gerald L. Princler
Abstract: Hybridoma tumor cell line A.T.C.C. No. HB8116. An anti-H-Y antigen monoclonal antibody substance, "Hyclonalan," produced by said cell line. Use of Hyclonalan in immunoselection methodology.
Abstract: A method for the synthesis of tetrakis-(6,6,7,7,8,8,8,-heptafluoro-2,2-dimethyl-3,5-octanedione) cerium (IV), [Ce(fod).sub.4 ] wherein the product is directly formed by reacting the deprotonated beta-diketonate ligand with a cerium (IV) salt, is disclosed.
Abstract: Crude interleukin-2 extract is subjected to group-selective dye-ligand absorption chromatography in one or more stages of purification with a matrix-gel medium consisting of a Blue A ligand or variant thereof or of a Green A ligand in a concentration of approximately 1.5 to 3.0 mg/ml of expanded matrix at a pH of approximately 6.8 to 8.5, a temperature of approximately 4.degree. to 40.degree. C., and a flowthrough rate of approximately 10 to 100 ml/h, employing an eluent. Either PHA-free or extremely pure interleukin-2 is obtained, depending on the overall number of purification stages.
Type:
Grant
Filed:
December 14, 1982
Date of Patent:
April 2, 1985
Assignee:
Biotest-Serum-Institut GmbH
Inventors:
Hans H. Sonneborn, Udo Schwulera, Hans Schleussner
Abstract: A new improved process of producing a rare earth metal alkoxide is now provided, which comprises reacting a rare earth metal carboxylate with an alkali metal alkoxide in an inert organic solvent under anhydrous conditions, and which can be conducted in a facile way and give the desired rare earth metal alkoxide of a high purity in a high yield.
Abstract: Mouse monoclonal antibody AbR.sub.24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the PA-MHA serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be G.sub.D3 ganglioside by compositional and partial structural analysis and by comparison with authentic G.sub.D3 by thin layer chromatography (TLC). AbR.sub.24 reacts with authentic G.sub.D3, but not with any other ganglioside tested. Using TLC and reactivity with AbR.sub.24, a wide range of cells and tissues was examined for the presence of G.sub.D3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR.sub.24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have T.sub.D3 and G.sub.M3 as major gangliosides. Other cells and tissues examined also contained G.sub.D3, but usually only in low amounts.
Type:
Grant
Filed:
April 2, 1982
Date of Patent:
March 26, 1985
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Clifford S. Pukel, Kenneth O. Lloyd, Luiz R. Travassos, Wolfgang G. Dippold, Herbert F. Oettgen, Lloyd J. Old
Abstract: A solution of a hydrophobic substituted, amino triphenyl methane leucocyanide dye in a clear, highly polar solvent free of hydroxyl groups with enough acid added to make the solution slightly acidic which is sensitive to small dosages of ionizing radiation and responds by permanently changing color. Up to one-half of the solution by weight can be replaced by a second solution of an aromatic solvent and an organic fluor. Another modification of the invention is a solution of a leucocyanide dye in a clear polar solvent which has an aromatic group, an organic fluor, and enough acid to make the solution slightly acidic.
Abstract: Murine-derived hybridoma tumor cell lines and monoclonal anti-Colony Stimulating Factor Subclass Number 1 antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of natural Colony Stimulating Factor Subclass Number 1 and for quantitative detection of colony Stimulating Factor Subclass Number 1 in fluid samples.
Abstract: An affinity immunoassay system in which a solid phase nonimmunological, group-specific ligand is used to insolubilize the analyte of interest either simultaneously, before or after binding all of the analyte with a labelled monospecific antibody and the concentration of the analyte is then determined by measuring the label activity present in the solid phase in relation to a single point calibrator solution containing a known amount of the analyte substance.
Abstract: A monoclonal antibody known as TA-1 directed against human T-cells is covalently linked to the toxin ricin and used to treat human donor bone marrow before the marrow is infused into a human recipient.
Type:
Grant
Filed:
July 19, 1982
Date of Patent:
February 19, 1985
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David M. Neville, Jr., Richard J. Youle
Abstract: The present disclosure relates to a solid phase immunoassay for the detection of Neisseria gonorrhoeae antigens in a clinical specimen, wherein the Neisseria gonorrhoeae antigens to be determined are coated or adsorbed on the solid phase.
Type:
Grant
Filed:
March 28, 1983
Date of Patent:
February 5, 1985
Assignee:
Abbott Laboratories
Inventors:
Dinah Abram, Alan S. Armstrong, John E. Herrmann, Chung-Mei Ling
Abstract: The present disclosure relates to a solid phase immunoassay for the detection of Chlamydia trachomatis antigens in a clinical specimen, wherein the Chlamydia trachomatis antigens to be determined are coated or adsorbed on the solid phase.
Type:
Grant
Filed:
March 28, 1983
Date of Patent:
February 5, 1985
Assignee:
Abbott Laboratories
Inventors:
Alan S. Armstrong, John E. Herrmann, Lawrence V. Howard
Abstract: A process for the detection of an antigen or antibody in a specimen which process comprises:(a) contacting said specimen with a substrate having bound thereon a mixture of antigens and antibodies to said antigen or antibody in said specimen, said antibodies and said antigens bound to said substrate being separately bound to said substrate and not in the form of an immune complex, incubating the so-contacted substrate and washing the substrate;(b) contacting the washed material of step `a` with a radioactive material labeled or enzyme labeled antibody or antigen, incubating the so-contacted material and washing the same; and(c) effecting radioimmunoassay if said antibody or antigen is radioactive or enzyme labeled immunoassay is said antibody or antigen is enzyme labeled.
Abstract: A method is provided for testing for particular antibodies in the serum of a patient. The antibodies may be those of systemic lupus erythematosus and may constitute IgG and IgM immunoglobulins. The IgG and IgM immunoglobulin may be individually labeled radioactively.An antigen (such as DNA) may be attached to a support such as sepharose. The attachment may be facilitated as by irradiation with ultraviolet light. The DNA may be single stranded or double stranded. When double-stranded DNA is used, single-stranded portions in the double strands may be removed as by a suitable enzyme.The particular antibodies may be attached to the antigen such as the supported DNA. An assay may then be provided to determine the attachment of the particular antibodies to the supported DNA.
Abstract: An assay for HLA D phenotype wherein antigen-pulsed monocytes are contacted with antigen-specific T lymphocytes or T cell hybridomas and the extent of selective binding between the pulsed monocytes and the T lymphocytes or T cell hybridomas determines HLA D phenotype of the monocyte. The assay is particularly useful for quickly typing donor tissue prior to transplantation.
Type:
Grant
Filed:
April 19, 1983
Date of Patent:
January 8, 1985
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed is the radiohalolabelling of metyrapone (1-propanone-1,2-di-(3-pyridinyl)-2-methyl), an 11Beta-hydroxylase inhibitor and of related compounds to form imaging agents for the adrenal cortex. Metyrapone was selectively converted to its mono-N-oxide. 4'-Bromo-metyrapone was obtained therefrom by a three-step conversion. Exchange labelling of the latter gave radiolabelled metyrapone. Found suitable as imaging agents are .sup.77 Br-4-bromo-metyrapone; .sup.131 l-4-iodo-metyrapone; .sup.123 l-4-iodometyrapone and their corresponding metyrapoles. Mixtures of these also can be used as imaging agents.
Abstract: An improved, more convenient, more sensitive test for detection of certain malignancies in human and animal subjects is disclosed. Sera from test subjects is mixed with labeled DNA in the presence of an enzyme-conjugated resin. Sera from normal and cancerous subjects react differently with the resin, permitting a diagnosis of the subject.
Abstract: The present invention relates to a novel method for the quantitative determination of PEP (progestagen-associated endometrial protein) in a body fluid by radioimmunoassay. The technique is useful in monitoring the function of the human endometrium.